Evidence map›Paper›PMID 39459978›Full record

ArticleViruses2024

Inflammasome-Driven Fatal Acute-on-Chronic Liver Failure Triggered by Mild COVID-19.

Vivian Chih-Wei Chen, Craig Ryan Joseph, Wharton O Y Chan, Wan Rong Sia, Qi Su, Xin Xiu Sam, Hemavathi Tamilarasan, Yun Yan Mah, Wei Lun Ng, Joe Yeong and 5 more

Abstract readCase Reports
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vivian Chih-Wei ChenProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0001-8757-0644
Craig Ryan JosephInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore.
Wharton O Y ChanProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0002-4526-470X
Wan Rong SiaProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0003-2694-4192
Qi SuProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0001-6556-1261
Xin Xiu SamDepartment of Anatomical Pathology, Singapore General Hospital, Singapore 169856, Singapore.
Hemavathi TamilarasanInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore.
Yun Yan MahProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
Wei Lun NgProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0003-1533-9325
Joe YeongInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore.ORCID 0000-0002-6674-7153
Lin-Fa WangProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0003-2752-0535
Thinesh L KrishnamoorthyDepartment of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 169608, Singapore.ORCID 0000-0002-5640-1079
Wei-Qiang LeowDepartment of Anatomical Pathology, Singapore General Hospital, Singapore 169856, Singapore.ORCID 0000-0001-6003-9837
Matae AhnProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0003-2114-8250
Wan Cheng ChowDepartment of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 169608, Singapore.ORCID 0000-0002-7567-999X

Funding

Agency for Science, Technology and Research I20AGAG602Agency for Science, Technology and Research I23D1AG048Agency for Science, Technology and Research IAF-ICP I2001E0065Agency for Science, Technology and Research IAF-ICP I2201E0014Ministry of Education MOE2019-T2-2-130Ministry of Health MOH-000561National Medical Research Council NMRC/OFLCG/002-2018National Medical Research Council OFLCG23may-0039
6 · The paper itself

Abstract

Inflammasome is linked to many inflammatory diseases, including COVID-19 and autoimmune liver diseases. While severe COVID-19 was reported to exacerbate liver failure, we report a fatal acute-on-chronic liver failure (ACLF) in a stable primary biliary cholangitis-autoimmune hepatitis overlap syndrome patient triggered by a mild COVID-19 infection. Postmortem liver biopsy showed sparse SARS-CoV-2-infected macrophages with extensive ASC (apoptosis-associated speck-like protein containing a CARD) speck-positive hepatocytes, correlating with elevated circulating ASC specks and inflammatory cytokines, and depleted blood monocyte subsets, indicating widespread liver inflammasome activation. This first report of a fatal inflammatory cascade in an autoimmune liver disease triggered by a mild remote viral infection hopes to elucidate a less-described pathophysiology of ACLF that could prompt consideration of new diagnostic and therapeutic options.

Indexed as

Acute-On-Chronic Liver FailureCOVID-19InflammasomesSARS-CoV-2CytokinesFatal OutcomeFemaleHepatitis, AutoimmuneHumansLiverMacrophagesMaleMiddle AgedCytokinesInflammasomesacute-on-chronic liver failureASCautoimmune hepatitisCOVID-19inflammasomeNLRP3primary biliary cholangitisSARS-CoV-2

Identifiers

PMID39459978
PMCPMC11512379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.